Clinical Trial

Self-sampling for Non-attenders to Cervical Cancer Screening

Study acronym: KOPRETINA
Recruiting
View on ClinicalTrials.gov →
Summary
The trial will evaluate whether self-sampling and human papillomavirus (HPV) testing may increase cervical cancer screening attendance among under-screened women in Czech Republic. Different ways of offering self-sampling device will be evaluated.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-01-09; most recent amendment 2026-03-19.
Trial Details
NCT Number NCT04226313
Lead Sponsor The Institute of Molecular and Translational Medicine, Czech Republic
Collaborators: National Institute for Cancer Research, Czech Republic
Conditions Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection
Enrollment 15,000 participants
Start Date 2019-09-23
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-23